Accession Number : ADA594751


Title :   Multifunctional Nanotherapeutic System for Advanced Prostate Cancer


Descriptive Note : Final rept. 30 Sep 2011-29 Sep 2013


Corporate Author : SOUTH DAKOTA STATE UNIV BROOKINGS


Personal Author(s) : Perumal, Omathanu


Full Text : http://www.dtic.mil/get-tr-doc/pdf?AD=ADA594751


Report Date : Oct 2013


Pagination or Media Count : 10


Abstract : The main goal of this study is to overcome docetaxel (DTX) resistance in prostate cancer cells by combined delivery of eIF4E siRNA and DTX using dendrimer as a nanocarrier. To this end the objective of this study is to prepare, characterize and test the feasability of the combination delivery approach in-vitro in DTX sensitive and resistant prostate cancer cells. During the last evaluation period we prepared and characterized the dendrimer-DTX conjugate and dendrimer-siRNA complex. During this evaluation period our goal was to optimize the delivery system, develop the DTX resistant prostate cancer cells and test the in-vitro efficacy of the multifunctional delivery system. The DTX resistant prostate cancer cells were developed by treating PC3 cells with sub-therapeutic concentration of DTX for 9 months and it was found to overexpress eIF4E. The multifunctional therapeutic system was able to overcome the resistance in PC3 cells and lowered the IC50 value in drug resistant PC3 cells. The siRNA reduced the levels of eIF4E and Myc in PC3 cells. Overall the outcomes from this study demonstrate the feasibility of developing a therapeutic strategy for drug resistant prostate cancer. Our future studies will focus on further optimizing the delivery system and testing the efficacy in-vivo in prostate cancer mouse model.


Descriptors :   *PROSTATE CANCER , DRUGS , FEASIBILITY STUDIES , THERAPY


Subject Categories : Anatomy and Physiology
      Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE